
Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.

Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.

This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.

Published: May 3rd 2016 | Updated:

Published: February 12th 2020 | Updated:

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
